VERTEX PHARMACEUTICALS INC / MA Quarterly Deferred Income Tax Assets, Net in USD from Q4 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
Summary
Vertex Pharmaceuticals Inc / Ma quarterly Deferred Income Tax Assets, Net history and growth rate from Q4 2018 to Q3 2024.
  • Vertex Pharmaceuticals Inc / Ma Deferred Income Tax Assets, Net for the quarter ending September 30, 2024 was $2.31B, a 33.5% increase year-over-year.
Deferred Income Tax Assets, Net, Quarterly (USD)
Deferred Income Tax Assets, Net, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $2.31B +$580M +33.5% Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $2.19B +$648M +42.1% Jun 30, 2024 10-Q 2024-08-02
Q1 2024 $1.96B +$603M +44.3% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $1.81B +$565M +45.3% Dec 31, 2023 10-Q 2024-11-05
Q3 2023 $1.73B +$566M +48.7% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $1.54B +$394M +34.5% Jun 30, 2023 10-Q 2023-08-02
Q1 2023 $1.36B +$414M +43.8% Mar 31, 2023 10-Q 2023-05-02
Q4 2022 $1.25B +$312M +33.4% Dec 31, 2022 10-K 2024-02-15
Q3 2022 $1.16B +$229M +24.5% Sep 30, 2022 10-Q 2022-10-28
Q2 2022 $1.14B +$191M +20% Jun 30, 2022 10-Q 2022-08-05
Q1 2022 $946M +$130M +15.9% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 $935M +$51.7M +5.86% Dec 31, 2021 10-K 2023-02-10
Q3 2021 $934M -$214M -18.6% Sep 30, 2021 10-Q 2021-11-03
Q2 2021 $953M -$262M -21.6% Jun 30, 2021 10-Q 2021-07-30
Q1 2021 $816M -$332M -28.9% Mar 31, 2021 10-Q 2021-04-30
Q4 2020 $883M -$308M -25.9% Dec 31, 2020 10-K 2022-02-09
Q3 2020 $1.15B -$268M -18.9% Sep 30, 2020 10-Q 2020-10-30
Q2 2020 $1.21B -$210M -14.8% Jun 30, 2020 10-Q 2020-07-31
Q1 2020 $1.15B -$320M -21.8% Mar 31, 2020 10-Q 2020-05-01
Q4 2019 $1.19B -$309M -20.6% Dec 31, 2019 10-K 2021-02-11
Q3 2019 $1.42B Sep 30, 2019 10-Q 2019-10-31
Q2 2019 $1.43B Jun 30, 2019 10-Q 2019-08-01
Q1 2019 $1.47B Mar 31, 2019 10-Q 2019-05-01
Q4 2018 $1.5B Dec 31, 2018 10-K 2020-02-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.